Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 15, 2019 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics’ Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure

NORCROSS, Ga., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that its largest...
December 20, 2018 08:30 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Announces Extension of $10 Million Line Credit

NORCROSS, Ga., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that its $10 million...
November 19, 2018 09:19 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Present at the 2nd Annual Anti-Fibrotic Drug Development Summit

NORCROSS, Ga., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H....
November 13, 2018 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update

NORCROSS, Ga., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
November 05, 2018 08:00 ET | Source: Galectin Therapeutics Inc.

Data Collected by Exalenz Bioscience in Galectin Therapeutics’ Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD Annual Meeting

NORCROSS, Ga., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that an abstract based...
October 15, 2018 10:22 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Participate in The ROTH Capital Battle of the NASH Thrones Investment Conference

NORCROSS, Ga., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will...
October 15, 2018 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Present at The ROTH Capital Battle of the NASH Thrones Investment Conference

NORCROSS, Ga., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will...
September 20, 2018 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics, Inc. Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial

Combination immunotherapy of GR-MD-02 and KEYTRUDA for all cohorts reported shows an Objective Response Rate of 50% (seven of fourteen patients). The published response rate of KEYTRUDA alone is 33%...
August 28, 2018 08:30 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference

NORCROSS, Ga., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H....
August 14, 2018 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Reports 2018 Second Quarter Financial Results and Provides Business Update

NORCROSS, Ga., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...